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1. Introduction 
Historically, tuberculosis (TB) has been associated with significant morbidity and mortality, 
and still remains a major global health problem. It is estimated that 2 billion people are 
latently infected with Mycobacterium tuberculosis, resulting in approximately 3 million deaths 
worldwide per year. Among the unique features of this organism is its ability to establish 
persistent infection, requiring prolonged antibiotic treatment in order to achieve clinical 
cure. The basic goals of anti-tuberculosis therapy include rapid killing of actively 
multiplying bacilli, prevention of acquired drug resistance, and sterilization of infected host 
tissues to prevent clinical relapse. Official guidelines recommend a minimum of 6 months of 
combination antibiotic therapy in order to achieve these goals. Clinical isolates in 
geographic areas with a high prevalence of drug resistance should be tested routinely for 
susceptibility to first-line anti-tuberculosis agents if resources permit, in order to optimally 
guide therapy (Karakousis 2009). The emergence of multidrug-resistant TB (MDR-TB), 
defined as resistance to the first-line drugs isoniazid and rifampicin, and extensively drug-
resistant TB (XDR-TB), defined as MDR-TB with additional resistance to fluoroquinolones 
and at least one of the injectable second-line drugs (capreomycin, kanamycin, and 
amikacin), poses formidable challenges to global TB control efforts. The high global 
incidence of drug-resistant TB, estimated annually to be ~500,000 cases of MDR-TB of which 
5% to 7% represent XDR-TB, underscores the need to understand the molecular mechanisms 
of drug resistance, with the ultimate goals of developing new techniques for rapid detection 
of drug resistance and identification of new drug targets. 
This chapter presents an updated review of the mechanisms of action and resistance of the 
main old and new anti-tuberculosis agents. 
2. Intrinsic and acquired drug resistance 
Intrinsic resistance refers to the innate ability of a bacterium to resist the activity of a 
particular antimicrobial agent through its inherent structural or functional characteristics. 
Intrinsic drug resistance in M. tuberculosis has been attributed to its unique cell wall 
properties, including the presence of mycolic acids, which are high-molecular-weight  
ǂ-alkyl,ǃ-hydroxy fatty acids covalently attached to arabinogalactan, and which constitute a 
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very hydrophobic barrier responsible for resistance to certain antibiotics (Karakousis, Bishai 
et al. 2004). In addition, M. tuberculosis possesses ǃ-lactamase enzymes, which confer 
intrinsic resistance to ǃ-lactam antibiotics, while efflux mechanisms appear to play an 
important role in resistance to antibiotics such as tetracycline and the aminoglycosides. 
Acquired drug resistance occurs when a microorganism obtains the ability to resist the 
activity of a particular antimicrobial agent to which it was previously susceptible. Acquired 
drug resistance in M. tuberculosis is caused mainly by spontaneous mutations in 
chromosomal genes, and the selective growth of such drug-resistant mutants may be 
promoted during suboptimal drug therapy (Kochi, Vareldzis et al. 1993). The rate of genetic 
mutations leading to resistance varies somewhat among anti-tuberculosis drugs, from a 
frequency of ~10-5-10-6 organisms for isoniazid to ~10-7-10-8 organisms for rifampin 
(Karakousis 2009). Since the bacterial burden typically present in pulmonary cavities does 
not exceed 1012 bacilli (Canetti 1965), combination therapy is highly effective for drug-
susceptible disease, and the risk for development of acquired drug resistance is minimized.   
3. Old TB drugs 
3.1 Isoniazid               
Isoniazid (isonicotinic acid hydrazide, INH) has been the most commonly used anti-
tuberculosis since recognition of its clinical activity in 1952 (Robitzek and Selikoff 1952). 
Consisting of a pyridine ring and a hydrazide group, INH is a nicotinamide analog, 
structurally related to the anti-tuberculosis drugs ethionamide and pyrazinamide. Because 
of its significant bactericidal activity, it has become a critical component of the first-line 
antituberculous regimens, although in the last two decades resistance to INH has been 
reported with increasing frequency. 
 
Isoniazid 
3.1.1 Mechanism of action 
INH appears to penetrate host cells readily (Mackaness and Smith 1952) and diffuses across 
the M. tuberculosis membrane (Suter 1952; Bardou, Raynaud et al. 1998). INH is a pro-drug, 
requiring oxidative activation by the M. tuberculosis catalase-peroxidase enzyme KatG 
(Zhang, Heym et al. 1992). Although the active metabolites of INH have been reported to 
inhibit multiple essential cellular pathways, including synthesis of nucleic acids 
(Gangadharam, Harold et al. 1963), phospholipids (Brennan, Rooney et al. 1970), and NAD 
metabolism (Zatman, Kaplan et al. 1954; Bekierkunst 1966), the primary pathway 
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responsible for the killing activity of the drug is mycolic acid synthesis (Winder and Collins 
1970; Takayama, Wang et al. 1972; Takayama, Schnoes et al. 1975). Thus, the activated form 
of the drug binds tightly to the NADH-dependent enoyl acyl carrier protein (ACP) 
reductase InhA (Banerjee, Dubnau et al. 1994), a component of the fatty acid synthase II 
system of mycobacteria, which is essential for fatty acid elongation (Quemard, Sacchettini et 
al. 1995). INH does not directly interact with InhA, as X-ray crystallographic and mass 
spectrometry data revealed that the activated form of INH covalently attaches to the 
nicotinamide ring of NAD bound within the active site of InhA, causing NADH to 
dissociate from InhA (Dessen, Quemard et al. 1995; Rozwarski, Grant et al. 1998). However, 
the precise mechanism by which INH kills M. tuberculosis remains to be elucidated.  
3.1.2 Mechanism of resistance  
Because INH is the most commonly used antituberculosis drug, resistance to INH occurs 
more frequently among clinical isolates than resistance to any other agent (Karakousis 2009).  
Mutations in INH-resistant clinical isolates are most commonly detected in the katG gene, 
occurring in 50–80% of cases, thus reducing the ability of the catalase-peroxidase to 
activate the INH pro-drug. The katG gene is located in a highly variable and unstable 
region of the M. tuberculosis genome, with missense and nonsense mutations, insertions, 
deletions, truncation and, more rarely, full gene deletions observed. Depending on the 
type of mutation, and the degree to which function of the KatG enzyme is preserved, the 
ensuing minimum inhibitory concentration (MIC) of isoniazid may range from 0.2 to 256 
mg/L. Point mutations in katG are more commonly observed than other types of 
mutations, and a single point mutation resulting in substitution of threonine for serine at 
residue 315 (S315T) accounts for the majority of INH resistance among clinical isolates 
(Marttila, Soini et al. 1998; Abate, Hoffner et al. 2001). The S315T mutation results in a 
significant reduction in catalase and peroxidase activity, and is associated with high-level 
INH resistance (MIC = 5–10 μg/mL) (Rouse, DeVito et al. 1996; Saint-Joanis, Souchon et 
al. 1999).  
INH resistance may also arise from mutations in inhA, resulting in reduced affinity of the 
enzyme for NADH without affecting its enoyl reductase activity (Basso, Zheng et al. 1998), 
or in the promoter region of the mabAinhA operon (Musser, Kapur et al. 1996), resulting in 
overexpression of the wild-type enzyme. Generally, mutations in inhA or in the promoter 
region of its operon usually confer low-level resistance (MIC = 0.2–1 mg/L) (Wade and 
Zhang 2004). In addition to conferring resistance to INH, mutations in inhA also cause 
resistance to the structurally related second-line drug ethionamide.  
Mutations in the ndh gene, which encodes a NADH dehydrogenase, confer resistance to 
INH and ethionamide in M. smegmatis (Miesel, Weisbrod et al. 1998), and have been 
detected in INH-resistant M. tuberculosis clinical isolates, which lack mutations in the katG or 
inhA genes (Lee, Teo et al. 2001). Defective NADH dehydrogenase could lead to an 
increased ratio of NADH/NAD, thereby interfering with KatG-mediated peroxidation of 
INH, or by displacing the INH/NAD adduct from the InhA active site (Miesel, Weisbrod et 
al. 1998). Furthermore, mutations in kasA and ahpC genes have been associated with INH 
resistance. Nevertheless, as many as a quarter of all clinical INH-resistant isolates do not 
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have mutations in any of the above genes, suggesting alternative mechanisms of INH 
resistance (Karakousis 2009). 
3.2 Rifampin and other rifamycins                    
The rifamycins were first isolated in 1957 from Amycolatopsis (formerly Streptomyces) 
mediterranei as part of an Italian antibiotic screening program (Sensi 1983). Their 
incorporation into the standard anti-tuberculosis regimen allowed reduction of the duration 
of treatment from 18 to 9 months. Although the early bactericidal activity of the rifamycins 
is inferior to that of INH, the former are the most potent sterilizing agents available in TB 
chemotherapy, continuing to kill persistent tubercle bacilli throughout the duration of 
therapy (Mitchison 1985; Grosset, Lounis et al. 1998). Rifampin is a broad-spectrum 
antibiotic and the most widely used rifamycin to treat TB. 
 
Rifampicin 
3.2.1 Mechanism of action 
Rifamycins contain an aromatic nucleus linked on both sides by an aliphatic bridge. The 
rifamycins easily diffuse across the M. tuberculosis cell membrane due to their lipophilic 
profile (Wade and Zhang 2004). Their bactericidal activity has been attributed to their 
ability to inhibit transcription by binding with high affinity to bacterial DNA-dependent 
RNA polymerase. Although the molecular target of rifampin has been well characterized, 
the precise mechanism by which this interaction leads to mycobacterial killing remains 
unclear.  
3.2.2 Mechanism of resistance 
Although INH monoresistance is relatively common in M. tuberculosis, resistance to 
rifampin alone is rare, and more than 90% of rifampin-resistant isolates are also resistant to 
INH. Therefore, rifampin resistance has been used as a surrogate marker for MDR-TB. 
Resistance to rifampin in M. tuberculosis arises at a frequency of 10-7 to 10-8 organisms, most 
commonly as single point mutations in the rpoB gene, which encodes the ǃ-subunit of RNA 
polymerase (Telenti, Imboden et al. 1993). In over 90% of rifampin-resistant clinical isolates, 
point mutations cluster in an 81-base pair “hot-spot” region between codons 507 and 533 of 
the rpoB gene, with mutations in codons 531 [Ser] and 526 [His] predominating 
(Ramaswamy and Musser 1998). However, a small percentage of rifampin-resistant isolates 
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(<5%) do not contain any mutations in the rpoB gene, suggesting alternative resistance 
mechanisms, potentially including altered rifampin permeability or mutations in other RNA 
polymerase subunits (Musser 1995).  
Higher doses of the rifamycins, especially rifapentine, have the potential to further shorten 
the duration of TB treatment. Therefore, there is renewed interest in establishing the 
maximally tolerated dose of these drugs, and a number of clinical trials are planned or 
underway to examine the safety, pharmacokinetics and efficacy of higher than standard 
doses of rifampicin or rifapentine in first-line TB treatment (Ginsberg 2010). 
3.3 Pyrazinamide                     
Since the discovery of pyrazinamide (PZA) in 1952 (Yeager, Munroe et al. 1952), and its 
routine use to treat TB, the duration of treatment required to achieve acceptable relapse 
rates has been reduced from 9–12 months to the current 6 months (Steele and Des Prez 
1988). Although its bactericidal activity is inferior to that of INH and rifampin (Jindani, Aber 
et al. 1980), the potent sterilizing activity and treatment-shortening potential of PZA has 
been attributed to the drug’s unique ability to target semi-dormant populations of bacilli 
residing within an acidic environment (Mitchison 1985).  
 
Pyrazinamide 
3.3.1 Mechanism of action 
PZA is an amide derivative of pyrazine-2-carboxylic acid and nicotinamide analog. Despite 
recognition of its anti-tuberculosis activity six decades ago, the mechanism of action of PZA 
remains poorly understood. PZA has been hypothesized to act against bacilli residing in 
acidified compartments of the lung that are present during the early inflammatory stages of 
infection (Mitchison 1985), since the drug’s sterilizing activity appears to be limited to the 
first 2 months of therapy (1986; 1986; 1991). PZA enters tubercle bacilli passively and via an 
ATP-dependent transport system (Raynaud, Laneelle et al. 1999). Intracellular accumulation 
of the drug occurs because of an inefficient efflux system unique to M. tuberculosis. PZA, like 
INH, is a pro-drug, requiring activation to its active form, pyrazinoic acid (POA), by the 
enzyme pyrazinamidase (PZase) (Konno, Feldmann et al. 1967; Scorpio and Zhang 1996). 
Uptake and intrabacillary accumulation of POA is enhanced when the extracellular pH is 
acidic (Zhang, Scorpio et al. 1999). The anti-tuberculosis activity of PZA has been attributed 
to disruption of the proton motive force required for essential membrane transport 
functions by POA at acidic pH (Zhang, Wade et al. 2003), although investigation into 
potential specific cellular targets is ongoing. 
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3.3.2 Mechanism of resistance 
PZA resistance has been attributed primarily to mutations in the pncA gene encoding PZase 
(Scorpio and Zhang 1996). Most mutations, including point mutations, deletions, and 
insertions, have been reported in a 561-bp region of the open reading frame or in an 82-bp 
region of its putative promoter (Scorpio, Lindholm-Levy et al. 1997; Jureen, Werngren et al. 
2008). The relatively high degree of diversity in pncA mutations among PZA-resistant 
clinical isolates has complicated the development of molecular assays for the rapid and 
economical detection of PZA resistance. A small percentage of isolates with high-level PZA 
resistance contain no mutations in pncA or its promoter, suggesting alternative mechanisms 
of resistance such as deficient uptake (Raynaud, Laneelle et al. 1999), enhanced efflux, or 
altered pncA regulation. 
The high specificity of PZA for M. tuberculosis, with little or no activity against M. bovis and 
other mycobacteria, is attributable to pncA mutations, which render PZase inactive in the 
latter mycobacterial species.  
3.4 Ethambutol                     
Ethambutol (EMB; dextro-2,2.-(ethylenediimino)-di-1-butanol) was initially reported to have 
anti-tuberculosis activity in 1961 and, together with INH, rifampin, and PZA, constitutes the 
modern-day short-course for the treatment of drug-susceptible TB. Like INH, EMB 
primarily kills actively multiplying bacilli and has very poor sterilizing activity. 
 
Ethambutol 
3.4.1 Mechanism of action  
The primary pathway affected by EMB appears to be that of arabinogalactan biosynthesis 
through inhibition of cell wall arabinan polymerization (Mikusova, Slayden et al. 1995). EMB 
also has been reported to inhibit several other cellular pathways, including RNA metabolism 
(Forbes, Kuck et al. 1962; Forbes, Kuck et al. 1965), transfer of mycolic acids into the cell wall 
(Takayama, Armstrong et al. 1979), phospholipid synthesis (Cheema and Khuller 1985; 
Cheema and Khuller 1985), and spermidine biosynthesis (Paulin, Brander et al. 1985). 
3.4.2 Mechanism of resistance 
Resistance to EMB in M. tuberculosis is usually associated with point mutations in the 
embCAB operon (Belanger, Besra et al. 1996). Genetic and biochemical studies have shown 
that the EmbA and EmbB proteins are involved in the formation of the proper terminal 
hexaarabinofuranoside motif during arabinogalactan synthesis (Escuyer, Lety et al. 2001), 
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while EmbC is involved in lipoarabinomannan synthesis (Zhang, Torrelles et al. 2003). As 
the majority of EMB-resistant clinical isolates contain mutations in the embB gene 
(Sreevatsan, Stockbauer et al. 1997; Telenti, Philipp et al. 1997; Ramaswamy, Amin et al. 
2000), EmbB is considered to be the main target of EMB, although X-ray crystallographic 
data supporting this interaction are lacking. More recently, the most commonly observed 
mutations in embB codon 306 have been reported to be associated with variable degrees of 
EMB resistance, indicating that such mutations may be necessary but not sufficient for high-
level EMB resistance. Other potential mutations involved in EMB resistance include a 
Gln379Arg substitution in M. tuberculosis embR, as well as mutations in the rmlD, rmlA2, and 
Rv0340 genes. As many as one quarter of all EMB-resistant M. tuberculosis isolates do not 
harbor mutations in any of the genes described above, suggesting alternative mechanisms of 
EMB resistance (Karakousis 2009). 
3.5 Aminoglycosides                    
The discovery of streptomycin in the early 1940s represented the first breakthrough in TB 
chemotherapy. Although relapse rates are comparable when streptomycin is substituted for 
EMB as the fourth drug in addition to INH, rifampin, and PZA, the poor oral absorption of 
streptomycin, which necessitates parenteral administration, as well as the toxicity profile of the 
aminoglycosides, have favored the use of EMB in first-line anti-tuberculosis therapy. Other 
aminoglycosides with significant antimycobacterial activity include kanamycin and amikacin. 
Aminoglycosides are used currently as second-line drugs primarily in the treatment of MDR-TB. 
 
Streptomycin 
3.5.1 Mechanism of action 
As in other bacteria, the mode of action of the aminoglycosides against mycobacterial 
species is through their binding to the 30S ribosomal subunit, which affects polypeptide 
synthesis, ultimately resulting in inhibition of translation. 
3.5.2 Mechanism of resistance 
Resistance to streptomycin and the other aminoglycosides in M. tuberculosis usually 
develops by mutation of the ribosome target binding sites. Interestingly, although cross- 
resistance is observed between amikacin and kanamycin (Allen, Mitchison et al. 1983), these 
drugs are not cross-resistant with streptomycin (Tsukamura and Mizuno 1975), suggesting 
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distinct mechanisms of resistance. Mutations in the rpsL gene, which encodes the ribosomal 
protein S12, account for approximately half of all streptomycin-resistant clinical isolates 
(Nair, Rouse et al. 1993; Cooksey, Morlock et al. 1996), with the K43R mutation 
predominating. In about 20% of streptomycin-resistant M. tuberculosis clinical isolates, such 
resistance is associated with mutations in the rrs gene, which are usually clustered in the 
regions surrounding nucleotides 530 or 912 (Douglass and Steyn 1993; Cooksey, Morlock et 
al. 1996). The particular vulnerability of rrs to mutation, leading to streptomycin resistance 
in M. tuberculosis and other slow-growing mycobacteria, can be explained by the fact that 
these mycobacterial species, unlike other bacteria, contain only a single copy of the rrs gene. 
Generally, mutations in the rpsL and rrs genes confer high-level (MIC > 1,000 mg/L) or 
intermediate-level (MIC = 64–512 mg/L) resistance to streptomycin (Sreevatsan, Pan et al. 
1996). On the other hand, mechanisms of low-level resistance to streptomycin (MIC = 4–32 
mg/L) remain largely undefined but may be attributable to changes in cell envelope 
permeability or diminished drug uptake (Honore and Cole 1994; Cooksey, Morlock et al. 
1996). More recently, it has been shown that mutations in gidB, which encodes a conserved 
S-adenosylmethionine-dependent 16S rRNA methyltransferase, can confer low-level 
resistance to streptomycin (Wong, Lee et al. 2011). 
3.6 Fluoroquinolones              
The fluoroquinolones (moxifloxacin, gatifloxacin, sparfloxacin, levofloxacin, ofloxacin, and 
ciprofloxacin), are bactericidal antibiotics with excellent activity against M. tuberculosis and 
are currently used as second-line drugs in TB treatment. New-generation fluoroquinolones 
[moxofloxacin, gatifloxacin] are under clinical evaluation as first-line antibiotics with the 
goal of shortening the duration of TB treatment. 
                  
Ciprofloxacin                                                        Moxifloxacin 
3.6.1 Mechanism of action 
Fluoroquinolones exert their powerful antibacterial activity by trapping gyrase and 
topoisomerase IV on DNA as ternary complexes, thereby blocking the movement of 
replication forks and transcription complexes (Drlica and Malik 2003). Unlike most other 
bacterial species, M. tuberculosis lacks topoisomerase IV, but contains the genes gyrA and 
gyrB encoding the A and B subunits, respectively, of DNA gyrase (Cole, Brosch et al. 1998). 
3.6.2 Mechanism of resistance 
Fluoroquinolone resistance in M. tuberculosis is most commonly associated with mutations 
in the conserved quinolone resistance-determining region (QRDR) of gyrA and gyrB 
involved in the interaction between the drug and DNA gyrase (Ginsburg, Grosset et al. 
2003). The degree of fluoroquinolone resistance is dictated by the specific amino acid 
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substitution in the QRDR, as well as the number of resistance mutations present. Therefore, 
while individual mutations in gyrA may confer low-level resistance (MIC > 2 mg/L) 
(Kocagoz, Hackbarth et al. 1996), high-level resistance to fluoroquinolones usually requires 
multiple mutations in gyrA, or concurrent mutations in gyrA and gyrB (Kocagoz, Hackbarth 
et al. 1996; Xu, Kreiswirth et al. 1996). The most frequently observed mutations associated 
with fluoroquinolone resistance in M. tuberculosis are at positions Ala-90 and Asp-94 in the 
gyrA gene. Codon 95 contains a naturally occurring polymorphism (Ser or Thr) that is not 
related to fluoroquinolone resistance, as it occurs in both fluoroquinolone-susceptible and 
fluoroquinolone-resistant strains. Interestingly, mutations at position 80 of gyrA have been 
reported to cause hypersusceptibility to fluoroquinolones, especially when present with 
other resistance mutations (Aubry, Veziris et al. 2006). Since mutations in the QRDR region 
of gyrA are identified in only 42–85% of fluoroquinolone-resistant clinical isolates, 
alternative mechanisms of resistance are presumed to exist, including the potential 
participation of efflux pumps. Although full cross-resistance is commonly observed across 
fluoroquinolones, von Groll et al. (Von Groll, Martin et al. 2009) recently reported a strain 
with an Asn-533-Thr mutation in gyrB that was resistant to moxifloxacin and gatifloxacin 
but susceptible to ofloxacin.  
3.7. Macrolides 
3.7.1 Mechanism of action                
The macrolides are broad-spectrum antibiotics, which exert their antibacterial effect by 
binding to the bacterial 50S ribosomal subunit and inhibiting RNA-dependent protein 
synthesis (Piscitelli, Danziger et al. 1992). However, these drugs have limited activity against 
wild-type M. tuberculosis (Bermudez and Yamazaki 2004). The possible role of macrolides in 
TB treatment is an area of active investigation, as recent studies have reported synergy of 
macrolides in combination with other antibiotics. 
 
Clarithromycin 
3.7.2 Mechanism of resistance  
Intrinsic resistance to the macrolides in M. tuberculosis has been attributed to low cell wall 
permeability and expression of the erm(37) gene encoding a 23S rRNA methyltransferase, 
which is present in all members of the M. tuberculosis complex but absent in nontuberculous 
mycobacteria (Buriankova, Doucet-Populaire et al. 2004). Subinhibitory concentrations of 
clarithromycin have been shown to cause induction of erm(37) expression and a 4- to 8-fold 
increase in MIC (Andini and Nash 2006). 
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3.8 Ethionamide         
Ethionamide, a synthetic compound structurally related to INH, is a pro-drug, requiring 
activation by the monooxygenase EthA (Baulard, Betts et al. 2000; DeBarber, Mdluli et al. 
2000; Vannelli, Dykman et al. 2002). Similar to INH, ethionamide inhibits mycolic acid 
synthesis by binding the ACP reductase InhA. Approximately three-quarters of M. 
tuberculosis isolates with high-level ethionamide resistance (MIC > 50 mg/L) have mutations 
in ethA or inhA (Morlock, Metchock et al. 2003). Recently, other potential mechanisms of 
resistance have been identified, as M. tuberculosis mshA deletion mutants were found to be 
defective in mycothiol biosynthesis and resistant to ethionamide, likely due to defective 
activation of the drug (Vilcheze, Av-Gay et al. 2008). 
 
Ethionamide 
3.9 Capreomycin         
Capreomycin is a macrocyclic polypeptide antibiotic isolated from Streptomyces capreolus  
(Karakousis 2009). Capreomycin, like streptomycin and kanamycin, inhibits protein 
synthesis through modification of ribosomal structures at the 16S rRNA (Wade and Zhang 
2004). Recent studies using site-directed mutagenesis have identified the binding site of 
capreomycin on 16S rRNA helix 44 (Akbergenov, Shcherbakov et al. 2011). In M. tuberculosis, 
resistance to capreomycin and kanamycin has been associated with mutations in the rrs 
gene encoding 16S rRNA (Taniguchi, Chang et al. 1997; Alangaden, Kreiswirth et al. 1998). 
Mutations in the gene tlyA encoding a 2'-O-methyltransferase of 16S rRNA and 23S rRNA 
have been implicated in resistance to capreomycin and viomycin (Johansen, Maus et al. 
2006), and such resistance is generally associated with the addition of methyl groups to 
rRNA rather than their loss (Sander, Meier et al. 1996). However, recent studies have shown 
that capreomycin-resistant strains lack mutations in tlyA (Jugheli, Bzekalava et al. 2009). 
 
Capreomycin 
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3.10 Cycloserine          
Cycloserine is a d-alanine analogue, which interrupts peptidoglycan synthesis by 
inhibiting the enzymes d-alanine racemase (AlrA) and d-alanine:d-alanine ligase (Ddl) 
(Caceres, Harris et al. 1997). Overexpression of M. tuberculosis AlrA and Ddl on a 
multicopy vector results in resistance to D-cycloserine in M. smegmatis and M. bovis BCG 
(Caceres, Harris et al. 1997; Feng and Barletta 2003), although whether similar 
mechanisms are responsible for cycloserine resistance in M. tuberculosis remain to be 
determined. 
 
Cycloserine 
3.11 Paraaminosalicylic acid             
Paraaminosalicylic acid (PAS) is thought to inhibit folic acid biosynthesis and uptake of iron 
(Wade and Zhang 2004). Mutations in the thyA gene encoding the enzyme thimidylate 
synthesis of the folate biosynthesis pathway have been identified in PAS-resistant  
M. tuberculosis clinical isolates, suggesting that PAS may act as a folate antagonist 
(Rengarajan, Sassetti et al. 2004). However, only slightly more than a third of the evaluated 
PAS-resistant strains had mutations in thyA, suggesting the existence of additional 
mechanisms of PAS resistance. Thr202Ala has been reported as the most common mutation 
associated with PAS resistance, although this mutation has also been identified in several 
PAS-susceptible isolates (Leung, Yip et al. 2010). 
 
Paraaminosalicylic acid 
4. New TB drugs 
Several new drugs have emerged recently as potential candidates for the treatment of TB. In 
most cases, their mechanism of action is distinct from that of the classical anti-TB drugs, 
although strains resistant to several of the novel drugs already have been described even 
prior to their routine clinical use.  
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4.1 Nitroimidazoles 
Reduced oxygen tension may be an important microenvironmental condition encountered 
by persistent bacilli within necrotic lung granulomas in the human host (Haapanen, Kass et 
al. 1959). Interestingly, although in vitro exposure to microaerophilic conditions renders M. 
tuberculosis less susceptible to killing by INH and rifampin, the bacilli become susceptible to 
metronidazole (Wayne and Sramek 1994; Wayne and Hayes 1996) a nitroimidazole drug 
used to treat anaerobic infections. Metronidazole, which becomes reductively activated by 
the pyruvate:ferredoxin oxidereductase system under anoxic conditions (Edwards 1993) 
lacks antituberculous activity in mouse models (Brooks, Furney et al. 1999; Klinkenberg, 
Sutherland et al. 2008) and in guinea pigs (Hoff, Caraway et al. 2008), but displays activity in 
M. tuberculosis-infected rabbits (Via, Lin et al. 2008). Clinical studies evaluating the activity 
of metronidazole against MDR-TB are ongoing. 
4.1.1 PA-824  
PA-824, a small molecule nitroimidazopyran related to metronidazole, exhibits bactericidal 
activity against actively multiplying and stationary-phase cultures of M. tuberculosis, as well 
as in murine and guinea pig models of TB infection (Stover, Warrener et al. 2000; Lenaerts, 
Gruppo et al. 2005). In addition, PA-824 is highly active against multidrug-resistant clinical 
isolates of M. tuberculosis (MIC < 1 μg/mL), suggesting no cross-resistance with current anti-
tuberculosis drugs (Lenaerts, Gruppo et al. 2005). Like metronidazole, PA-824 is a pro-drug 
requiring reductive activation of an aromatic nitro group, which involves an F420-
dependent glucose-6-phosphate dehydrogenase encoded by Rv0407 (fgd1) (Stover, Warrener 
et al. 2000) and deazaflavin-dependent nitroreductase (Ddn) encoded by Rv3547 (Singh, 
Manjunatha et al. 2008), in order to exert its antitubercular effect. The activity of PA-824 is at 
least partially mediated through inhibition of the oxidation of hydroxymycolates to 
ketomycolates, a terminal step in mycolic acid synthesis (Stover, Warrener et al. 2000). 
Recently, formation of the des-nitroimidazole metabolite of PA-824 was shown to generate 
reactive nitrogen species, including nitric oxide, which appears to contribute to the killing 
activity of PA-824 and may explain the activity of the drug against non-replicating bacilli 
(Singh, Manjunatha et al. 2008). Similar to INH, resistance to PA-824 is most commonly 
mediated by mutations that lead to loss of pro-drug activation, including those in the genes 
Rv0407 and Rv3547 encoding the activating enzymes.  
 
PA-824 
4.1.2 OPC-67683                 
OPC-67683 is a nitro-dihydro-imidazooxazole derivative with potent activity against drug-
susceptible M. tuberculosis and MDR-TB. The drug exerts its killing activity by inhibiting the 
synthesis of methoxy- and keto-mycolic acids. The substitution of OPC-67683 for INH and 
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EMB in the standard regimen alongside rifampin and PZA led to more rapid sterilization of M. 
tuberculosis-infected mouse lungs (Matsumoto, Hashizume et al. 2006). Like the other 
nitroimidazoles, OPC-67683 is a pro-drug requiring reductive activation by M. tuberculosis. As 
in the case of PA-824, mutations in the Rv3547 gene have been identified in strains resistant to 
OPC-67683, indicating defective drug activation (Matsumoto, Hashizume et al. 2006).  
 
OPC-67683 
4.2 TMC207             
TMC207 (also named R207910 or “J compound”) is a first-in-class anti-TB diarylquinoline 
with bactericidal and sterilizing activities against drug-susceptible and drug-resistant M. 
tuberculosis in vitro and in animal models, including in a murine model of latent TB infection 
(Zhang, Li et al. 2011). Mouse model studies suggest a synergistic relationship between 
TMC207 and PZA (Matteelli, Carvalho et al. 2010). TMC207 inhibits ATP synthase, a critical 
enzyme in the synthesis of ATP for M. tuberculosis (Andries, Verhasselt et al. 2005). The 
addition of TMC207 to standard therapy for MDR-TB significantly reduced the time to 
conversion to a negative sputum culture and increased the proportion of patients with 
conversion of sputum culture as compared with placebo (Diacon, Pym et al. 2009). 
Resistance to TMC207 is mediated by mutations in the atpE gene encoding the 
transmembrane and oligomeric C subunit of ATP synthase, typically at positions 63 or 66 
(Petrella, Cambau et al. 2006). However, more recent studies have shown that a majority of 
in vitro-generated mutants resistant to TMC207 lacked mutations in atpE, indicating 
alternative mechanisms of drug resistance (Huitric, Verhasselt et al. 2010).  
 
TMC207 
4.3 SQ109                  
SQ109 was identified by screening a large synthesized combinatorial library based on the 
1,2-ethylenediamine structure of EMB, and was found to have limited toxicity and potent 
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activity against intracellular bacilli as well as in a murine model of chronic TB infection 
(Protopopova, Hanrahan et al. 2005). Early clinical data reveal the drug’s potential to enhance 
the treatment of TB during the first 2 months of intensive therapy and also to treat MDR-TB 
(Lalloo and Ambaram 2010). Whether upregulation of ahpC expression, observed in strains 
resistant to INH, EMB, and SQ109, plays a role in resistance to SQ109 or merely reflects a 
compensatory metabolic mechanism remains to be determined (Jia, Coward et al. 2005). 
 
SQ109 
4.4 Phenothiazines 
The antipsychotic phenothiazine drug thioridazine has been reported to be active against 
drug-susceptible and drug-resistant M. tuberculosis, both in macrophages (Ordway, Viveiros et 
al. 2003) as well as in murine models (van Soolingen, Hernandez-Pando et al. 2010). Although 
serum concentrations above the MIC for M. tuberculosis (8-16 mg/L range) cannot be safely 
attained in humans, thioridazine still has potential as an antimycobacterial drug because of 
intracellular accumulation, such that concentrations inside macrophages are at least 10-fold 
higher than in serum. Despite the favorable toxicity profile of thioridazine relative to 
chlorpromazine and other phenothiazines, cardiac arrhythmia associated with prolongation of 
the QTc interval remains a risk. Thioridazine has been used successfully to cure patients with 
XDR-TB in Argentina and as salvage therapy in similar patients in India (Amaral, Boeree et al. 
2010). The mechanism of action of thioridazine is likely multifactorial, as the drug appears to  
act on enzymes involved in fatty acid metabolism and membrane proteins, particularly efflux 
pumps (Dutta, Mazumdar et al. 2011), in addition to inhibiting type II NADH:menaquinone 
oxidoreductase as a phenothiazine (Weinstein, Yano et al. 2005). Mechanisms of M. tuberculosis 
resistance to the phenothiazines remain to be elucidated.  
 
Thioridazine 
4.5 Oxazolidinones 
Oxazolidinones are a new chemical class of synthetic antibiotics related to cycloserine with 
broad-spectrum activity against gram-positive pathogens through inhibition of protein 
synthesis. 
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4.5.1 Linezolid                    
Linezolid is the first compound belonging to the oxazolidinone class approved for clinical 
use. Due to its ability to penetrate macrophages, linezolid is active against intracellular 
bacilli, exerting its activity by binding to the ribosomal 50S subunit and thus inhibiting an 
early step in protein synthesis (Zhang 2005). Linezolid is most commonly used to treat drug-
resistant TB, but its use has been limited by toxicity concerns, particularly hematological 
disturbances such as leukopenia and thrombocytopenia, as well as peripheral neuropathy, 
which may be irreversible. While resistance to linezolid in M. tuberculosis clinical isolates is 
rarely reported, in vitro-selected mutants with high-level resistance to linezolid (MIC = 16–
32 mg/L) have been found to contain mutations at G2061T and G2576T in the 23S rRNA 
gene (Hillemann, Rusch-Gerdes et al. 2008). On the other hand, mutants with lower level 
linezolid resistance (MIC = 4–8 mg/L) lack mutations in the 23S rRNA gene, implicating 
other possible mechanisms of resistance.  
 
Linezolid 
4.5.2 PNU-100480 
PNU-100480, another oxazolidinone, has been shown to have more potent activity against 
M. tuberculosis than linezolid, as the MIC of PNU100480 is half that of linezolid, and is as 
bactericidal as isoniazid in an acute model of TB infection in mice (Cynamon, Klemens et al. 
1999). Recent studies in the mouse model have shown that the addition of PNU-100480 to 
the standard first-line regimen of rifampin, INH, and PZA can shorten the duration of 
treatment necessary to prevent relapse (Williams, Brickner et al. 2009), suggesting that this 
drug may have sterilizing activity against drug-susceptible and drug-resistant  
M. tuberculosis. Recent Phase I studies have shown that PNU-100480 is safe and well 
tolerated at all tested doses, and exhibits synergy with PZA in an ex vivo whole-blood 
culture assay (Wallis, Jakubiec et al. 2011). Resistance mechanisms are expected to be similar 
to those of linezolid. 
4.5.3 AZD5847 
AZD5847 was originally designed for treatment of gram-positive infections, but was later 
repositioned for TB treatment with the goal of improving the toxicity profile associated with 
linezolid, including inhibition of mitochondrial protein synthesis, thrombocytopenia, and 
myelosuppression (Koul, Arnoult et al. 2011). Like linezolid, AZD5847 has bactericidal 
activity against M. tuberculosis in macrophages, as well as in murine models of acute and 
chronic TB infection. Recent Phase I trials revealed that oral administration of the drug up to 
800 mg twice daily for 14 days was satisfactorily tolerated in healthy volunteers. Although 
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bioavailability decreases with increasing dose, this effect may be largely compensated if 
taken within 2 hours of meals, and the exposures achieved in man correspond to efficacious 
exposures in the mouse model of TB infection (B. Subramanian, Gordon Research 
Conference on Tuberculosis Drug Development, July 2011). Phase 2 studies to be conducted 
in South Africa are in the planning stage. 
4.6 Benzothiazinones 
The 1,3-benzothiazin-4-ones (BTZs) represent a new class of drugs, which have activity 
against M. tuberculosis in vitro, ex vivo, and in murine TB models (Makarov, Manina et al. 
2009). BTZs are activated in M. tuberculosis by reduction of an essential nitro group to a 
nitroso derivative, which then specifically reacts with a cysteine residue in the active site of 
the enzyme decaprenylphosphoryl-ǃ-D-ribose 2'-epimerase (DprE1) (Trefzer, Rengifo-
Gonzalez et al. 2010). Inhibition of this enzymatic activity abolishes the formation of 
decaprenylphosphoryl arabinose, a key precursor that is required for the synthesis of the 
cell-wall arabinans, thus causing bacterial lysis and death (Makarov, Manina et al. 2009). 
Although spontaneous BTZ-resistant laboratory mutants were found to have a Ser or Gly 
substitution at codon Cys387 of dprE1, resistance to BTZs has not been reported in clinical 
M. tuberculosis isolates (Pasca, Degiacomi et al. 2010). Recently, a novel resistance 
mechanism to BTZ was described in M. smegmatis involving the overexpression of the 
nitroreductase NfnB, which leads to the inactivation of the drug by reduction of a critical 
nitro-group to an amino-group (Manina, Bellinzoni et al. 2010). However, M. tuberculosis 
seems to lack nitroreductases able to inactivate BTZs.   
5. Antibiotic tolerance 
Antibiotic tolerance refers to the ability of nonreplicating bacteria to resist killing by cell 
wall-active antibiotics, which target actively multiplying organisms (Tomasz, Albino et al. 
1970). This phenomenon is distinct from drug resistance (intrinsic or acquired), since it is 
not attributable to genetic mutations, and the organisms regain susceptibility to these 
antibiotics once the stress conditions have been removed and bacterial growth resumes. 
The prolonged duration of antibiotic treatment required to eradicate TB is believed to 
reflect the altered physiological state of “persistent” bacilli, which have developed 
tolerance to standard anti-tuberculosis drugs, particularly to isoniazid, which inhibits 
mycolic acid synthesis (Karakousis, Williams et al. 2008). One of the major challenges 
facing current TB drug development programs is to identify compounds with sterilizing 
activity against antibiotic tolerant “persisters”, with the ultimate goal of shortening the 
duration of TB treatment. 
6. Conclusion 
The principal etiology of drug-resistant TB remains inadequate and/or incomplete 
treatment, including poor medical adherence to the standard treatment regimen and the 
addition of a single active drug to a failing drug regimen (Sharma and Mohan 2006). Given 
the increasing global prevalence of drug-resistant TB, it is of paramount importance to 
understand the mode of action of each drug as well as the molecular basis of drug 
resistance. Novel anti-TB drugs, which are safe, able to shorten the course of treatment, 
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effective against drug-resistant strains and latent TB infection, are urgently needed, 
especially in the era of MDR- and XDR-TB. 
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